CD4 and neoplasm: Additionally, mice receiving SDT+anti-PD-L1 therapy to their primary tumour have been observed to have significantly higher levels of infiltrating CD4+ and CD8 + T-cells in any residual off-target tumour tissue, compared to those who did not receive SDT+anti-PD-L1 therapy.